Eptifibatide

Administration

• Type: Antiplatelet
• Dosage Forms: INJ
• Routes of Administration: IV
• Common Trade Names: Integrilin

Adult Dosing

Acute Coronary Syndrome

• 2 mcg/kg/min IV
  • Start 180 mcg/kg up to 22.6 mg IV x1
  • Max: 15 mg/h infusion

PCI

• 2 mcg/kg/min IV
  • Start 180 mcg/kg up to 22.6 mg IV x1
  • Max: 15 mg/h infusion
  • Repeat bolus x1 10 min after initial dose

Pediatric Dosing

Safety/efficacy not established in pediatric patients

Special Populations

Pregnancy Rating

• Benefits outweigh risks during pregnancy
• Risk of maternal hemorrhage during delivery
• Risk of fetal bleeding

Lactation risk

• May use when breastfeeding

Renal Dosing

• Adult:
  • CrCl <50: Decrease infusion to 1 mcg/kg/min, max 7.5 mg/h
  • HD: Avoid use
• Pediatric: Unavailable

Hepatic Dosing

• Adult: Not defined
• Pediatric: Unavailable

Contraindications

• Allergy to class/drug
• Bleeding diathesis history
• Active abnormal bleeding w/in 30 days
• Major surgery w/in 6 weeks
• Stroke w/in 30 days
• Hemorrhagic stroke history
• Platelet < 100,000
• SBP > 200, DBP > 110
• Dialysis

Adverse Reactions

Serious

• Bleeding
• Intracranial hemorrhage
• Thrombocytopenia
• Anaphylaxis

Common

• Bleeding
• Hypotension

Pharmacology

• Half-life: 2.5 hours
• Metabolism: Other
• Excretion: Urine 50%

Mechanism of Action

• Reversibly binds to platelet glycoprotein IIb/IIIa receptors, reducing platelet aggregation

See Also

• Antiplatelet medications
• Antiplatelet agent reversal